Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 9/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 9/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 7/20 | 0.40 |
| ▸ | CA9 | Q16790 | 6/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA3 | P07451 | 4/20 | 0.39 |
| ▸ | CA4 | P22748 | 4/20 | 0.39 |
| ▸ | CA6 | P23280 | 4/20 | 0.39 |
| ▸ | CA5A | P35218 | 4/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416459 | 0.86 | TSHR (0.58) | TSHRCA12CA14LMNAKDM4E | |
| SCHEMBL23650051 | 0.85 | TSHR (0.56) | TSHRCA12CA14LMNAKDM4E | |
| SCHEMBL26611174 | 0.83 | TSHR (0.54) | TSHRCA12CA14LMNAKDM4E | |
| SCHEMBL23650054 | 0.83 | TSHR (0.54) | TSHRCA12CA14LMNAKDM4E | |
| SCHEMBL26611365 | 0.83 | TSHR (0.54) | TSHRCA12CA14LMNAKDM4E | |
| SCHEMBL23650053 | 0.83 | TSHR (0.54) | TSHRCA12CA14LMNAKDM4E | |
| SCHEMBL26611184 | 0.83 | TSHR (0.54) | TSHRCA12CA14LMNAKDM4E | |
| SCHEMBL26611327 | 0.83 | TSHR (0.54) | TSHRCA12CA14LMNAKDM4E | |
| SCHEMBL12873626 | 0.79 | TSHR (0.52) | TSHRCA12CA14LMNAKDM4E | |
| SCHEMBL8316410 | 0.78 | TSHR (0.41) | TSHRCA12CA14LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115806532-A | Preparation method of impurities in MIT | 大连百傲化学股份有限公司 | 2023-03-17 | — | — | CN | claimed |
| EP-4688741-A1 | COMPOUNDS FOR TREATING FIBROTIC DISEASES | Meta-Immune, Inc. (KR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024249867-A1 | COMPOUNDS FOR TREATING FIBROTIC DISEASES | AM SCIENCES (KR) | 2024-12-05 | — | — | WO | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| EP-3880666-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| EP-3880666-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| CN-115806532-A | Preparation method of impurities in MIT | 大连百傲化学股份有限公司 | 2023-03-17 | — | — | CN | disclosed |
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-7928264-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2011-04-19 | — | — | US | disclosed |
| CN-101039902-B | Aminoalcohol derivatives | ASTELLAS PHARMA INC | 2010-11-10 | — | — | CN | disclosed |
| EP-1791811-B1 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2009-12-23 | — | — | EP | disclosed |
| US-20090253683-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | ASUBIO PHARMA CO., LTD (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090253683-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | ASUBIO PHARMA CO., LTD (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20080039506-A1 | Aminoalcohol Derivatives | ASTELLAS PHARMA INC. (JP) | 2008-02-14 | — | — | US | disclosed |
| CN-101039902-A | Aminoalcohol derivatives | ASTELLAS PHARMA INC (JP) | 2007-09-19 | — | — | CN | disclosed |
| EP-1791811-A1 | AMINOALCOHOL DERIVATIVES | Astellas Pharma Inc. (JP) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006033446-A1 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2006-03-30 | — | — | WO | disclosed |
| WO-1997031902-A1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | TSHR 4300/4885CA12 2983/4885CA14 3599/4885 |
| US-11773058-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, NLRP1 | TSHR 1360/4885CA12 2645/4885CA14 2653/4885 |
| US-20090253683-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | CMA1, CPA3, SI | TSHR 3978/4885CA12 352/4885CA14 180/4885 |
| US-20080039506-A1 | Aminoalcohol Derivatives | HRH4, HRH2, CBR3 | TSHR 2359/4885CA12 1617/4885CA14 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.